JERSEY CITY, NJ, UNITED STATES - Dec 2, 2019 - TrialScope, the global leader in clinical trial transparency and disclosure compliance solutions, has worked with EMD Serono, the North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, to launch a new website, https://clinicaltrials.emdgroup.com. This site is designed to educate and inform patients, caregivers, the public, patient advocacy groups and healthcare professionals (HCPs) about the clinical trial journey, as well as provide specific information about clinical trials conducted by Merck KGaA, Darmstadt, Germany, and its affiliates.

In an effort to keep clinical trial participants fully informed, the website provides an overview of the different phases of research, as well as outlines each step the patient will encounter through the clinical trial process. The site also provides access to trial results and other available post-trial information, such as plain language summaries and clinical study report synopses. This is made possible through the TrialScope Engage™ platform that automatically syncs approved clinical trial data from TrialScope Disclose™, the global disclosure system used by Merck KGaA, Darmstadt, Germany. The site also provides impactful information about clinical research to healthcare professionals, which helps them raise awareness about the importance of clinical trials and discuss potential participation in clinical trials with their patients. An extensive FAQ section, with more than 30 questions and answers, provides a comprehensive overview of clinical trials.

“Both EMD Serono and TrialScope share a commitment to clinical trial transparency, awareness and patient engagement,” said TrialScope CEO Jeff Kozloff. “Together, we sought input from multiple patient stakeholders to develop an informative and well-designed site that will help accelerate patient knowledge, understanding and connections to relevant clinical trial information.”

To ensure that the website content meets the needs of patients, TrialScope and EMD Serono worked with the Center for Information and Study on Clinical Research Participation (CISCRP) to gather feedback from patients and the public. According to CISCRP, 75 percent of the general public is willing to participate in a clinical trial, yet only 30 percent have a basic understanding of what clinical research is. Insights gleaned from people who had previously searched for trials guided not only the content but the manner in which it is presented.

About TrialScope 

TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 16 of the top 20 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit TrialScope.com. 

AboutMerckKGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. In the U.S. and Canada, Merck KGaA, Darmstadt,

Germany operates its healthcare business as EMD Serono. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.

About CISCRP

The Center for Information and Study on Clinical Research Participation is a first-of-its-kind nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process.